

Precision Therapeutics, Inc. Bibliography

Articles/Book Sections

Mi Z, Holmes, FA, et al. (2008) " Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients." *AntiCancer Research* 2008 May-Jun;28(3B):1733-40.

Heinzman JM, Brower SL, Bush JE, Sliverman JF. (2007) Ex vivo enrichment of malignant carcinoma cells in primary culture. *Pathology*, 39 (5), 0031-3025.

Brower SL, Fensterer JE, Bush JE. (2007) The ChemoFx[®] Assay: An *Ex Vivo* Chemo-Sensitivity and Resistance Assay for Predicting Patient Response to Cancer Chemotherapy. In: *Methods in Molecular Biology, Molecular Medicine and Biotechnology*. J. Walker Ed.

Gallion HH, Christopherson WA, et al. (2006) Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. *International Journal of Gynecological Cancer* 16 (1), 194–201. doi:10.1111/j.1525-1438.2006.00301.x.

Peters D, Freund J, et al. (2005). Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. *Mol Cancer Ther* 4(10): 1605-16.

Kornblith P, Ochs RL, et al. (2004). Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma. *International Journal of Gynecological Cancer* 14: 607-615.

Marsh J, Donovan M, et al. (2004). Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents. *Journal of Neurooncology* 66: 81-90.

Ochs RL, Chattopadhyay A, et al. (2004). A phenotypic cell culture assay for predicting anticancer drug responses. *Preclinica* 2(3): 205-212.

Ochs RL, Burholt D, et al. (2004). The ChemoFx[®] Assay: An Ex Vivo Cell Culture Assay for Predicting Anticancer Drug Responses. *Methods in Molecular Medicine*, vol. 110: Chemosensitivity: Vol. 1: In Vitro Assays. R. Blumenthal. Totowa, NJ, Humana Press Inc. 110: 155-172.

Kornblith P, Wells A, et al. (2003). Breast cancer-response rates to chemotherapeutic agents studied in vitro. *Anticancer Research* 23: 3405-3412.

Kornblith P, Wells A, et al. (2003). In vitro responses of ovarian cancers to platinum and taxanes. *Anticancer Research* 23: 543-548.

Ochs RL, Fensterer J, et al. (2003). Evidence for the isolation, growth, and characterization of malignant cells in primary cultures of human tumors. *In Vitro Cellular & Developmental Biology - Animal* 39: 63-70.

Ness RB, Wisniewski SR, et al. (2002). Cell viability for drug testing in ovarian cancer: in vitro kill versus clinical response. *Anticancer Research* 22: 1145-1150.

Kornblith P, Burholt D. (2001). *Chemosensitivity Testing. Tumors of the Pediatric Central Nervous System.* R. Keating, J. Goodrich and P. RJ. New York, Thieme.

Letwin RL (2001). "Chemosensitivity Testing" *Clinical Journal of Oncology Nursing* 5(5): 195-200.

Letwin, RL (2001). Chemosensitivity Testing: Individualized Patient Therapy. *Journal of Gynecologic Oncology Nursing* 11: 63-65.

Abstracts

Gabrin MJ, Holmes FA, Backner A, Bush JE, Mi Z, O'Shaughnessy J. (2008) Feasibility of ChemoFx Assay to Predict Pathologic Response in Neoadjuvant Breast Cancer. In: *Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA.* Philadelphia (PA): AACR; 2008. Abstract nr 3661.

Silverman JF, Heinzman J, Brower S, Bush J. (2007) The cytopathologist's role in chemo-response testing. *Mod Pathol.* 20: USCAP Annual Meeting

Silverman J, Heinzman J, Brower S, Bush J (2007) A new technique for assessment of tumor cell viability for chemo-response testing: a concordance study. *Mod Pathol.* 20: USCAP Annual Meeting.

Holmes FA, Osborne C, et al. (2006) Feasibility of testing core needle breast biopsies *ex vivo* in the ChemoFx[®] assay: substudy results from US oncology trial 02-103. San Antonio Breast Cancer Symposium Meeting Abstracts, Dec 2006

O'Shaughnessy J, Holmes F, et al. (2006) Feasibility of testing core needle biopsies *ex vivo* in the ChemoFx assay. *Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 20073*

Dupree B, Wells A, et al. (2006) Breast biopsies obtained with MAMMOTOME[®] device can be tested *ex vivo* with ChemoFx[®] assay. Annual Meeting of the American Association for Cancer Research. April 2006; 2006: 1285.

Gallion H, Nickles Fader A, et al. (2006) ChemoFx[®] assay is an independent predictor of response to platinum-based chemotherapy in primary ovarian cancer. Society of Gynecologic Oncology Poster Session: Thursday, March 23, 2006

Nickles Fader A, Kelley J., et al. (2005). ChemoFx® Assay is an Independent Predictor of Response to Platinum-Based Chemotherapy in Primary Ovarian Cancer. Mid-Atlantic Gynecologic Oncology Society, 2005 Meeting. Wrightsville Beach, North Carolina.

Gallion HH., Piwowar H, et al. (2005). Uterine cancers: heterogeneity of response to chemotherapy ex vivo, Abstract #168. 2005 Annual Meeting on Women's Cancer Society of Gynecologic Oncology.

Kornblith P, Wells A, et al. (2005). Comparison of combination vs. single agent chemotherapeutic responses in primary cultures of human breast cancer cells, Abstract #831. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.

Nickles Fader A, Comerci J, et al. (2005). Ex vivo assay prediction of progression free interval following platinum chemotherapy in primary ovarian cancer, Abstract #5098. Journal of Clinical Oncology, 2005 Annual Meeting Proceedings.

Nickles Fader A, Kelly J, et al. (2005). Ex vivo assay prediction of progression free interval following platinum chemotherapy in primary ovarian cancer. Western Association of Gynecologic Oncologists, 2005 Meeting. Santa Fe, New Mexico.

Peters D, Freund J, et. al. (2005). Use of expression arrays to identify genes from ovarian cancer cells that are associated with carboplatin sensitivity and resistance, Abstract #4524. Annual Meeting of the American Association for Cancer Research. Anaheim, CA.

Tevar AD, Thambi-Pillai T, et. al. (2005). Utility of in vitro chemosensitivity testing of primary and metastatic hepatobiliary neoplasms, Abstract #4256. Journal of Clinical Oncology, 2005 Annual Meeting Proceedings.

Gallion HH, Christopherson WA, et al. (2004). Progression-free interval in ovarian cancer and predictive value of an ex vivo chemosensitivity assay. 5th Annual International Conference on Ovarian Cancer. M.D. Anderson Cancer Center.

Gallion HH, Christopherson WA, et al. (2004). Ex vivo chemoresponse assay of ovarian cancer predicts clinical outcome. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) **22**(14S): 5074.

Coleman R, Herzog T, et al. (2004). An ex vivo chemoresponse assay predicts carboplatin-induced progression-free interval in ovarian cancer. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings **22**(14S): 5134.

Ochs RL, Gallion HH, et al. (2004). Heterogeneity in chemoresponsiveness of ovarian cancer as demonstrated by an ex vivo chemo response assay. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) **22**(14S): 5059.

Ochs, RL, Piwowar HA, et al. (2004). Heterogeneity in chemoresponsiveness of tumor cells ex vivo, Abstract #2086. Annual Meeting of the American Association for Cancer Research.

Kornblith, P, Wells A, et al. (2003). In vitro comparison of response of doxorubicin/cyclophosphamide in combination versus use as individual agents in primary breast cancer, Abstract # 223. Journal of Clinical Oncology, 2003 ASCO Annual Meeting Proceedings 22:56.

Ochs RL, J Fensterer, et al. (2003). In vitro cell models for drug discovery: evidence for the isolation and growth of malignant cells in primary cultures of human tumors. Annual Meeting of the American Association for Cancer Research. Toronto, Ontario.

Rosenblum E, Mistovich J, et al. (2002). Co-expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor-AB (PCGF-AB) in cultured human astrocytic tumor cells. Annual Meeting of the American Association for Cancer Research.

Rosenblum E, Donovan-Peluso M. (2002). In vitro production of angiogenesis factors by cultured human breast tumor cells. Annual Meeting of the American Association for Cancer Research.

Donovan-Peluso M, Rosenblum E, et al. (2001). Matrix-Metalloproteinase-9 (MMP-9), Vascular Endothelial Growth Factor (VEGF), and Angiogenin (ANG) expression in vitro by astrocytic tumor cells, Abstract #3884. Annual Meeting of the American Association for Cancer Research.

Marsh JW, Donovan-Peluso M, et al. (2001). Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents, Abstract #1938. Annual Meeting of the American Association for Cancer Research.

Wahlberg BJ, Burholt D, et al. (2001). "Measurement of NK activity by the microcytotoxicity assay (MCA): a new application for an old assay." Journal of Immunological Methods 253(1-2).

Donovan-Peluso M., Burholt D, et al. (2000). Vascular Endothelial Growth Factor (VEGF) expression by cultured ovarian tumor cells correlates with chemotherapeutic cytotoxicity, Abstract #1057. Annual Meeting of the American Association of Cancer Research.

Donovan-Peluso M., Burholt D, et al. (2000). Metastatic disease to the central nervous system is responsive to chemotherapeutic agents in vitro. Annual Meeting of the American Association of Neurological Surgeons.

Burholt D, Christopherson WA, et al. (1999). Chemosensitivity of primary and recurrent ovarian carcinoma cells in tissue culture. Annual Meeting of the American Association for Cancer Research.

Donovan-Peluso M, Rosenblum E. (1999). Expression of angiogenesis factors by cultured primary human brain tumor cells. Annual Meeting of the American Association of Neurological Surgeons/Congress of Neurological Surgeons.

Donovan-Peluso M, Rosenblum E, et al. (1999). Functional urokinase can be measured directly in medium concentrates from cultured tumor cells in vitro. Annual Meeting of the American Association for Cancer Research.

Kornblith P, Burholt D, et al. (1999). Patterns of in vitro chemosensitivity responses of primary human meningioma cell cultures. Annual Meeting of the American Association of Neurological Surgeons.

Schenken L, Rosenblum E, et al. (1999). In vitro production of tumor associated antigens (TAAs) in cultured human ovarian carcinomas: CA 125, CA 15.3, CEA, Abstract #1850. Annual Meeting of the American Association for Cancer Research.

Van Thiel DH, Friedlander J, et al. (1999). Chemosensitivity of primary hepatic neoplasms: A new approach to the treatment of difficult tumors. Annual Meeting of the American Association for the Study of Liver Diseases.

Burholt D, Naus GJ, et al. (1998). Patterns of in vitro response in ovarian cancer. Annual Meeting of the American Association for Cancer Research.

Covelli M, Burholt D, et al. (1998). In vitro chemosensitivity of primary vs. recurrent ovarian carcinoma. Mid-Atlantic Gynecologic Oncology Society.

Kornblith P, Burholt D, et al. (1998). Differential response of primary oligodendroglioma cell cultures to nitrosoureas, Abstract. Annual Meeting of the Association of Neurological Surgeons/Congress of Neurological Surgeons.

Kornblith P, Burholt D, et al. (1998). Patterns of in vitro chemosensitivity responses of primary human glioma cell cultures. American Association of Neurological Surgeons.

Kornblith P, Naus GJ, et al. (1998). Approach to the analysis of the effects of cisplatin in primary brain tumor cultures. Annual Meeting of the American Association for Cancer Research.

Burholt D, Kornblith P, et al. (1997). Differential chemosensitivity responses of glioblastoma cell lines, Abstract #1513. Annual Meeting of the American Association of Neurological Surgeons.

Schulder M, Burholt D, et al. (1997). "In vitro examination of gliomas after radiosurgery, Abstract." LINAC Radiosurgery Annual Meeting.

Werts, ED, Burholt D, et al. (1997). Variables in in vitro short term radiation response. Annual Meeting of the American Radium Society.